Enanta Pharmaceuticals, Inc.
Every calculator, already run for ENTA
Open the full toolkit →You have the numbers on ENTA. Get the argument.
A written report on which of these readings actually decide the outcome for Enanta Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering ENTAAnalyst Price Target Disagreement for Enanta Pharmaceuticals, Inc.
Wall Street's bull case implies +52% from the current price; the bear case implies +45%. Analysts are relatively aligned on ENTA's range.
Ownership & short interest
Insider Trading Activity for ENTA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treat…
ENTA — frequently asked
Is ENTA a buy right now?
Wall Street's consensus rating on Enanta Pharmaceuticals, Inc. is none across 5 analysts, with a mean price target of $19.80 (+51% vs. the current $13.13). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ENTA's next earnings date?
Enanta Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 16, 2026. A full ENTA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Enanta Pharmaceuticals, Inc.?
Analysts covering Enanta Pharmaceuticals, Inc. (ENTA) range from a bear-case target of $19.00 to a bull-case high of $20.00, with a mean consensus target of $19.80 across 5 analysts. The spread of $1.00 (8% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Enanta Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Enanta Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ENTA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Enanta Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.